18:11 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

AmpliPhi reports data from expanded access program for bacteriophages

AmpliPhi Biosciences Corp. (NYSE-M:APHB) reported data from seven patients with serious, life-threatening infections who did not respond to antibiotics from an expanded access program showing that AB-SA01 or AB-PA01 (Biophage-PR, AmpliPhage-001) in combination with best...
19:50 , Aug 3, 2017 |  BC Innovations  |  Strategy

FDA's phage philosophy

Against a backdrop of doubt about the regulators’ outlook for bacteriophage therapeutics, FDA is assuring drug developers the re-emerging modality is firmly on the table. The position should assuage at least some concerns in a...
21:38 , Feb 23, 2017 |  BC Innovations  |  Tools & Techniques

Showdown: bacteria vs. virus

Drug developers are starting to revisit bacteriophages as a solution for two of the biggest questions in translational research: how to treat resistant bacterial infections, and how to manipulate the human microbiome. A spate of...
00:49 , Dec 17, 2013 |  BC Extra  |  Financial News

AmpliPhi raises $18 million

AmpliPhi Biosciences Corp. (OTCBB:APHB) raised $18 million through the sale of 72 million shares at $0.25 in a private placement. The price is a 44% discount to the company's close of $0.45 on Friday, the...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

AmpliPhi BioSciences preclinical data

In a mouse model of acute P. aeruginosa infection, BioPhage-PR reduced viral load after 6 hours vs. ciprofloxacin-treated mice. All mice survived at 24 hours post-infection and BioPhage-PR and ciprofloxacin each led to an about...